Silence Therapeutics plc Stock London S.E.
Stocks
SLN
GB00B9GTXM62
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 592M 801M 689M 650M 1.11B 76.62B 1.12B 7.74B 2.98B 38.86B 3.01B 2.94B 123B | P/E 2026 * |
-25x | P/E 2027 * | -20.1x |
|---|---|---|---|---|---|
| Enterprise Value | 459M 621M 534M 504M 859M 59.4B 866M 6B 2.31B 30.13B 2.33B 2.28B 95.7B | EV / Sales 2026 * |
1,424x | EV / Sales 2027 * | 557x |
| Free-Float |
69.35% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Silence Therapeutics plc
| 1 day | -0.93% |
| Manager | Title | Age | Since |
|---|---|---|---|
Iain Ross
CEO | Chief Executive Officer | 72 | 2025-11-30 |
Rhonda Hellums
DFI | Director of Finance/CFO | 54 | 2022-01-31 |
Curtis Rambaran
CTO | Chief Tech/Sci/R&D Officer | - | 2020-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
David Lemus
BRD | Director/Board Member | 63 | 2018-06-20 |
Iain Ross
CHM | Chairman | 72 | 2003-12-31 |
Tim McInerney
BRD | Director/Board Member | 65 | 2025-05-04 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.93% | -2.73% | - | - | 816M | |
| -0.56% | -8.08% | -3.88% | +10.58% | 46.38B | |
| -2.08% | -3.57% | +402.72% | +533.09% | 44.51B | |
| +0.12% | -5.27% | +39.94% | +20.50% | 42.3B | |
| -2.62% | -5.76% | +8.88% | +77.44% | 39.91B | |
| -1.26% | -3.37% | +11.87% | +40.55% | 32.79B | |
| +0.16% | -3.65% | - | - | 17.13B | |
| -0.54% | -1.72% | +22.34% | +115.10% | 16.36B | |
| -0.03% | -3.46% | +12.68% | +30.90% | 14.31B | |
| -1.92% | -6.94% | +78.12% | +36.68% | 13.29B | |
| Average | -0.97% | -4.30% | +71.58% | +108.10% | 29.66B | |
| Weighted average by Cap. | -1.09% | -4.54% | +87.11% | +129.36% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 322K 436K 375K 354K 603K 41.7M 608K 4.22M 1.62M 21.15M 1.64M 1.6M 67.19M | 751K 1.02M 873K 824K 1.4M 97.07M 1.42M 9.81M 3.78M 49.24M 3.81M 3.73M 156M |
| Net income | -42.14M -57M -49.02M -46.25M -78.77M -5.45B -79.48M -551M -212M -2.76B -214M -209M -8.78B | -71.01M -96.06M -82.61M -77.95M -133M -9.18B -134M -928M -357M -4.66B -361M -353M -14.8B |
| Net Debt | -133M -180M -155M -146M -249M -17.21B -251M -1.74B -670M -8.73B -676M -661M -27.73B | -174M -235M -202M -191M -325M -22.51B -328M -2.28B -876M -11.42B -884M -865M -36.26B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
